Literature DB >> 3996169

The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population.

A J Boulton, G Knight, J Drury, J D Ward.   

Abstract

The prevalence of symptomatic sensorimotor polyneuropathy has been determined in a population of 382 insulin-treated diabetic subjects aged 15-59 yr. Forty-one subjects (10.7%) were found to have diabetic neuropathy, according to strict diagnostic criteria that required the presence of symptoms and signs of nerve dysfunction in the absence of peripheral vascular disease. There was a significant correlation between glycosylated hemoglobin levels and motor conduction velocity in the median and peroneal nerves in all subjects. This finding further emphasizes the importance of metabolic factors related to hyperglycemia in the impaired nerve function seen in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3996169     DOI: 10.2337/diacare.8.2.125

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  30 in total

1.  Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy.

Authors:  L Wuarin-Bierman; G R Zahnd; F Kaufmann; L Burcklen; J Adler
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

2.  Subclinical diabetic neuropathy: similarities between electrophysiological results of patients with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P H Hendriksen; P L Oey; G H Wieneke; B Bravenboer; J D Banga
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

3.  Improved technique for testing autonomic dysfunction: evaluation of transient behaviour of the autonomic response.

Authors:  S Prună
Journal:  Med Biol Eng Comput       Date:  1990-03       Impact factor: 2.602

Review 4.  Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.

Authors:  E A Masson; A J Boulton
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

5.  Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.

Authors:  G D Valk; A C Kappelle; A M Tjon-A-Tsien; B Bravenboer; K Bakker; R P Michels; C M Groenhout; F W Bertelsmann
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

6.  Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function.

Authors:  M E Plater; I Ford; M T Dent; F E Preston; J D Ward
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

Review 7.  Diabetic neuropathies. Current concepts in prevention and treatment.

Authors:  J D Ward
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

8.  Peripheral nerve function in relation to quality of metabolic control in diabetes.

Authors:  F W Bertelsmann; J J Heimans; J C van Rooy; C Popp-Snijders; E A van der Veen
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

9.  Prevalence and forms of neuropathic morbidity in 800 diabetics.

Authors:  J A O'Hare; F Abuaisha; M Geoghegan
Journal:  Ir J Med Sci       Date:  1994-03       Impact factor: 1.568

10.  Power spectral analysis of the electrocardiogram in diabetic children.

Authors:  M D Rollins; J G Jenkins; D J Carson; B G McClure; R H Mitchell; S Z Imam
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.